Early Detection Research Network


This biomarker is also known as:
  • KLK6,
  • kallikrein-related peptidase 6,
  • Serine protease 18,
  • SP59,
  • Bssp,
  • PRSS18,
  • Klk7,
  • Neurosin,
  • Zyme,
  • HK-6,
  • Kallikrein-6,
  • Serine protease 9,
  • Protease M,
  • PRSS9,
  • KLK-6,


Serine protease M expressed on epithelial cell surface and released in ECM. Tumor cells treated with a neutralizing KLK6 antibody migrate less than control cells, suggesting a role in invasion and metastasis. Overexpressed in primary breast tumors but not expressed in metastatic tumors.


There are no datasets associated with this biomarker.

QA State: Accepted
Type: Protein

The following organs have data associated with this biomarker…


Phase: Three
QA State: Accepted


Amplification of a chromosome 19q region with the entire kallikrein family associated with ovarian cancer.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. KLK6 alone was not a strong predictor.

Supporting Study Data

The following studies/protocols provide evidence supporting KLK6 indications for the Ovary…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Version 5.0.2